Innovation Medical(002173)

Search documents
项目试点领航“健康城市”新境界
Xin Hua Ri Bao· 2025-09-13 20:18
Group 1 - The core viewpoint of the articles highlights the advancements in healthcare services and the implementation of innovative medical practices in Nantong, focusing on improving elderly care and integrating technology into healthcare [1][2][3][4][5][6][7] Group 2 - Nantong has launched the "Disability and Dementia Prevention Intervention Course," which has expanded from 4 to 18 communities, benefiting over 500 elderly individuals [1] - The city has established a local standard for elderly disability and dementia intervention, marking a significant step in enhancing healthcare for the aging population [1] - The "Five Integrations" approach in Nantong's medical innovation aims to enhance healthcare resources by merging various sectors, including basic research, clinical innovation, and industry collaboration [2] - The establishment of a regional demonstration medical innovation platform is expected to improve healthcare quality and accessibility [2] - The introduction of an AI diagnostic platform has significantly reduced the time for detecting bone density issues, showcasing the integration of technology in clinical settings [3] - Nantong's digital regulatory platform has improved oversight of healthcare institutions, generating over 124,000 prescription warnings and ensuring timely responses to potential issues [4] - The city has implemented a "Cardiac Network" in grassroots healthcare, equipping community health service stations with portable ECG devices to enhance emergency response capabilities [5] - Nantong's collaboration with grassroots health centers to create a "shared Chinese medicine pharmacy" has improved access to traditional medicine for over 1,500 residents [6] - The city is exploring the establishment of nursing homes in primary healthcare institutions to meet the growing demand for integrated medical and nursing services [7] - Nantong aims to create a healthcare service system that is more reliable, effective, and satisfactory for the public, with a focus on enhancing the quality of medical facilities [7]
生物药资产爆发后 中国创新医疗器械何时迎来DeepSeek一刻
Di Yi Cai Jing· 2025-09-13 09:50
不过,与对外授权如火如荼的创新药发展相比,中国的创新医疗器械要获得全球市场认可,挑战仍然很 大。在葛均波看来,这些挑战一方面是由于我国创新医疗器械起步仍然较晚,长期以模仿为主,原创思 维有待加强;另一方面也是因为我国医疗器械的创新生态链还不够成熟,资本和商业化的能力需要进一 步提升。 今年上半年,中国医疗器械行业也发生了多起对外授权,例如康蒂思与博迈医疗球囊扩张导管的合作, 但与创新药动辄数亿美元的对外授权规模相比,并未引发资本市场的波动。 而从过去几年国内获批的创新产品来看,创新医疗器械的数量并不少于创新药。来自国家药监局的数据 显示,"十四五"期间,我国共批准创新药210个和创新医疗器械269个。 今年中国创新生物药对外授权引发全球关注。相关数据显示,上半年创新药对外授权金额近660亿美 元,让全世界见证了中国生物医药的DeepSeek一刻。 不过在医疗器械领域,中国创新产品的DeepSeek一刻尚未来临。创新药的出海路径是否能在创新器械 领域重演,是业内热议的话题。 从模仿到创新 9月13日,在中国心血管医生创新俱乐部(CCI)成立十周年大会上,中国心血管创新医疗器械领头 人、中国科学院院士、复旦大学附 ...
深度|生物药资产爆发后,中国创新医疗器械何时迎来DeepSeek一刻
Di Yi Cai Jing· 2025-09-13 09:44
中国的创新医疗器械要获得全球市场的认可,挑战仍然很大。 今年中国创新生物药对外授权引发全球关注。相关数据显示,上半年创新药对外授权金额近660亿美 元,让全世界见证了中国生物医药的DeepSeek一刻。 为何创新器械授权难 微光医疗创始人CEO朱锐对第一财经记者表示:"中国创新医疗器械目前还没有到爆发点,创新器械爆 发的路径与创新药有较大的差异。创新药把靶点改一下,就成了一个新的专利,但医疗器械的小创新仍 会涉及知识产权问题。" 不过在医疗器械领域,中国创新产品的DeepSeek一刻尚未来临。创新药的出海路径是否能在创新器械 领域重演,是业内热议的话题。 从模仿到创新 9月13日,在中国心血管医生创新俱乐部(CCI)成立十周年大会上,中国心血管创新医疗器械领头 人、中国科学院院士、复旦大学附属中山医院心内科主任葛均波教授表示,中国创新药对外授权如今已 经占据了全球的半壁江山,大量源自于中国的创新药获得了全球的认可,这也为中国创新医疗器械的发 展增添了信心,期待未来有更多的创新医疗器械能走向世界。 回顾过去十年CCI的发展,葛均波称,中国心血管介入医疗器械在很长一段时间内高度依赖进口,价格 高昂,我们最初是希望 ...
掘金医疗黄金赛道,中银医药主题基金打造医药板块布局利器
Zhong Guo Zheng Quan Bao· 2025-09-11 04:54
Core Viewpoint - The pharmaceutical sector in the A-share market has shown structural performance, with the innovative drug index rising by 60.77% year-to-date, significantly outperforming the overall A-share index by 22.14% [1] Group 1: Pharmaceutical Sector Performance - The pharmaceutical sector has been active this year, with innovative drug indices leading the gains [1] - The performance of pharmaceutical-themed mutual funds has attracted investor attention, with notable returns reported [1] - Zhongyin Fund's pharmaceutical-themed funds have ranked well among peers, with Zhongyin Innovation Medical A achieving top rankings over various time frames [1] Group 2: Fund Manager Insights - Fund manager Zheng Ning employs a long-term pricing focus, filtering out market noise to concentrate on long-term implied returns [3] - The performance of Zhongyin Hong Kong Stock Connect Pharmaceutical A has shown significant growth, with a net value growth rate of 70.08% in the first half of 2025 [3] - Zheng Ning has managed multiple funds, consistently achieving competitive returns compared to benchmarks [4][6] Group 3: Market Drivers - The recent rise in the innovative drug sector is driven by fundamental improvements, including advancements in R&D, successful profit realization, and favorable policies [2] - The innovative drug industry is expected to have substantial growth potential, becoming a strategic industry in China's export structure and a key pillar in the global pharmaceutical industry [2]
广发创新医疗两年持有期混合增聘程文文
Zhong Guo Jing Ji Wang· 2025-09-09 07:36
中国经济网北京9月9日讯 今日,广发基金公告,广发创新医疗两年持有期混合增聘程文文。 程文文2019年7月至2021年6月任中意资产管理有限责任公司跨境业务部助理研究员,2021年6月至 2022年10月任长盛基金管理有限公司研究部行业研究员。2022年10月24日加入广发基金管理有限公司, 曾任研究发展部行业研究员。 广发创新医疗两年持有期混合A/C成立于2021年3月19日,截至2025年9月8日,其今年来收益率为 77.27%、76.80%,成立来收益率为-9.22%、-10.82%,累计净值为0.9078元、0.8918元。 | 基金名称 | 广发创新医疗两年持有期混合型证券投资基金 | | --- | --- | | 基金简称 | 广发创新医疗两年持有期混合 | | 基金主代码 | 010731 | | 基金管理人名称 | 广发基金管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》、 | | | 《基金管理公司投资管理人员管理指导意见》、 | | | 《广发创新医疗两年持有期混合型证券投资基金 | | | 基金合同》 | | 基金经理变更类型 | 增聘基金经理 | | 新任 ...
国泰创新医疗混合发起A:2025年上半年利润286.31万元 净值增长率29.47%
Sou Hu Cai Jing· 2025-09-08 15:49
AI基金国泰创新医疗混合发起A(018159)披露2025年半年报,上半年基金利润286.31万元,加权平均基金份额本期利润0.2221元。报告期内,基金净值增 长率为29.47%,截至上半年末,基金规模为1261.4万元。 该基金属于偏股混合型基金,长期投资于医药医疗股票。截至9月5日,单位净值为1.323元。基金经理是邱晓旭,目前管理3只基金近一年均为正收益。其 中,截至9月5日,国泰创新医疗混合发起A近一年复权单位净值增长率最高,达86.15%;国泰产业精选混合A最低,为28.59%。 基金管理人在半年报中表示,我们以前瞻成长为核心方向,看好商业化持续兑现的创新药企及其产业链,AI 赋能带来实质收入和盈利能力提升的新医疗服 务公司两大主线。而在趋势投资和逆向投资的结构平衡上,相比上半年,我们更看好院内标的的复苏,包括部分创新器械、集采落地后高耗、专科药等领 域。 截至9月5日,国泰创新医疗混合发起A近三个月复权单位净值增长率为35.91%,位于同类可比基金9/138;近半年复权单位净值增长率为52.47%,位于同类 可比基金44/138;近一年复权单位净值增长率为86.15%,位于同类可比基金18/13 ...
国家药监局批准多个创新医疗器械产品上市
Zhong Guo Zhi Liang Xin Wen Wang· 2025-09-08 04:35
Group 1 - The National Medical Products Administration has approved the launch of several innovative medical devices, including stents and X-ray computed tomography equipment [1][2] - Jiangsu Changyida Medical Technology Co., Ltd. has developed an innovative product, the "Intracranial Aneurysm Assisting Embolization Stent," which features a self-expanding elastic structure with adjustable length and angle to reduce vascular damage and enhance wall adherence [1] - Nanjing (Nantong) Medical Device Co., Ltd. has introduced the "Pulmonary Artery Thrombectomy Stent System," designed to address pulmonary artery embolism, utilizing a fixed sleeve design to minimize deformation during the release and retrieval of the thrombectomy basket [1] Group 2 - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. has launched a fully automated cell morphology analyzer that significantly improves the accuracy of white blood cell identification and abnormal sample screening, benefiting more patients [1] - Neusoft Medical Systems Co., Ltd. has developed an innovative X-ray computed tomography device that offers higher spatial resolution and the ability to obtain multiple energy images from a single scan, enhancing clinical imaging diagnostics [2]
全国8款产品进入创新医疗器械特别审批通道
Su Zhou Ri Bao· 2025-09-08 00:43
近年来,省药监局苏州检查分局、省药监局审评核查苏州分中心在提供常态化政策咨询、技术指导 的基础上,组建专班、协同发力,根据企业实际需求提供定制化服务,结出丰硕成果。截至9月5日,苏 州已有70款创新医疗器械进入特别审查程序,分别占全国的11%和江苏省的61%;有34款已成功上市, 分别占全国的9%和江苏省的65%。 5日,全国又有8款产品通过审查,进入国家创新医疗器械特别审批通道,可优先审查、更快投入市 场,其中一半产品由苏州企业申报。 根据国家药监局医疗器械技术评审中心发布的《创新医疗器械特别审查结果公示(2025年第8 号)》,全国共有8款产品获批进入审批"快车道",其中4款为苏州企业申请,包括苏州美创医疗科技有 限公司申请的可控直径TIPS覆膜支架系统、苏州英诺科医疗科技有限公司申请的镁合金空心接骨螺 钉、春风化雨(苏州)智能医疗科技有限公司申请的脊柱外科手术导航定位系统、景昱医疗科技(苏 州)股份有限公司申请的植入式脑深部神经刺激器。 ...
机构今日抛售阳光电源等20股,买入锦浪科技2.72亿元





3 6 Ke· 2025-09-05 11:29
Group 1 - On September 5, a total of 41 stocks were identified with institutional activity, with 21 stocks showing net buying and 20 stocks showing net selling [1] - The top three stocks with the highest net buying by institutions were Jinlang Technology, Deye Shares, and Tianhua New Energy, with net buying amounts of 272 million, 194 million, and 127 million respectively [1] - The top three stocks with the highest net selling by institutions were Sunshine Power, XianDao Intelligent, and Innovation Medical, with net outflow amounts of 677 million, 437 million, and 171 million respectively [1]
龙虎榜丨机构今日抛售这20股,买入锦浪科技2.72亿元
Di Yi Cai Jing· 2025-09-05 10:00
Core Insights - On September 5, a total of 41 stocks were involved with institutional investors, with 21 showing net buying and 20 showing net selling [1] - The top three stocks with the highest net buying by institutions were Jinlang Technology, Deye Shares, and Tianhua New Energy, with net buying amounts of 272 million, 194 million, and 127 million respectively [1] - The top three stocks with the highest net selling by institutions were Sunshine Power, Xian Dao Intelligent, and Innovation Medical, with net selling amounts of 677 million, 437 million, and 171 million respectively [1] Institutional Net Buying Summary - Jinlang Technology: 19.99% increase, net buying of 272.17 million [2] - Deye Shares: 10.00% increase, net buying of 194.18 million [2] - Tianhua New Energy: 20.01% increase, net buying of 127.13 million [2] - Other notable net buyers include Meibang Clothing (3.02%, 107.69 million) and Fangzheng Technology (10.05%, 91.54 million) [2] Institutional Net Selling Summary - Sunshine Power: 16.67% decrease, net selling of 677.49 million [4] - Xian Dao Intelligent: 20.01% decrease, net selling of 437.08 million [4] - Innovation Medical: 7.16% decrease, net selling of 171.01 million [4] - Other notable net sellers include Tianyue Advanced (20.00%, -560.38 million) and Yiwai Lithium Energy (16.59%, -470.42 million) [3][4]